- Home
- YYAI vs NERV Comparison
YYAI vs NERV Comparison
Compare YYAI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- NERV
- Stock Information
- Founded
- YYAI 2015
- NERV 2007
- Country
- YYAI Hong Kong
- NERV United States
- Employees
- YYAI N/A
- NERV N/A
- Industry
- YYAI
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- NERV Health Care
- Exchange
- YYAI NYSE
- NERV Nasdaq
- Market Cap
- YYAI 19.1M
- NERV 16.0M
- IPO Year
- YYAI N/A
- NERV 2014
- Fundamental
- Price
- YYAI $0.83
- NERV $2.23
- Analyst Decision
- YYAI
- NERV Hold
- Analyst Count
- YYAI 0
- NERV 1
- Target Price
- YYAI N/A
- NERV $5.00
- AVG Volume (30 Days)
- YYAI 367.5K
- NERV 37.0K
- Earning Date
- YYAI 03-04-2025
- NERV 02-20-2025
- Dividend Yield
- YYAI N/A
- NERV N/A
- EPS Growth
- YYAI N/A
- NERV N/A
- EPS
- YYAI N/A
- NERV N/A
- Revenue
- YYAI N/A
- NERV N/A
- Revenue This Year
- YYAI N/A
- NERV N/A
- Revenue Next Year
- YYAI N/A
- NERV N/A
- P/E Ratio
- YYAI N/A
- NERV N/A
- Revenue Growth
- YYAI N/A
- NERV N/A
- 52 Week Low
- YYAI $0.81
- NERV $2.06
- 52 Week High
- YYAI $53.00
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- YYAI 28.83
- NERV 50.40
- Support Level
- YYAI $1.16
- NERV $2.07
- Resistance Level
- YYAI $1.52
- NERV $2.39
- Average True Range (ATR)
- YYAI 0.21
- NERV 0.12
- MACD
- YYAI 0.06
- NERV -0.01
- Stochastic Oscillator
- YYAI 2.38
- NERV 48.48
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.